NR4A1 and breast cancer: The pCR rates and the extent of benefit obtained with pertuzumab were lower in the subgroup of patients with hormone receptor-positive BC (6% difference in pCR) compared to patients with hormone receptor-negative tumors (26.4% difference in pCR) (18).